Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. - Wikidata - awgldk - TriplyDB

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

http://www.wikidata.org/entity/Q35214924

about

Histone Deacetylases and Their Inhibition in Candida Species The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications Drosophila as an In Vivo Model for Human Neurodegenerative Disease Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis.Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma Quantitative structure-activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries.Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome.Drug development: Lessons from nature.The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation.Novel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosis Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice Medical management for neurosurgical related seizures.Mining the epigenetic landscape of tissue polarity in search of new targets for cancer therapy.The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.A seasonal switch in histone deacetylase gene expression in the hypothalamus and their capacity to modulate nuclear signaling pathways.Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo.Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.

P2860

Q26740146-EA5710D3-17B5-4A06-A1AE-F47DEAAC4F6F Q26771181-D9CF939A-BD98-4311-ACE2-8C4503BA5180 Q26771601-10F7E7D4-61BA-4998-8D14-28C3A4064083 Q26783014-37B8BE33-1811-4528-887F-52339482727B Q28073020-CEE4AB04-773A-4EAF-A186-4A7A7761E7F2 Q28074465-B89BAA4D-931B-4ED7-B9A7-B4DFC9462B93 Q28088777-1F614E25-8BD8-4783-B229-55BA9E1B3FA1 Q28829359-F5F637BA-851F-4515-B0FC-38C4FE7C92F2 Q30251920-0C111614-9772-4C24-8EE9-359123A83B59 Q31040399-9B0F73BD-5941-4E50-A928-C27FF4A49A28 Q33437948-80DE22A0-BBA8-4772-B407-C89B7C40E1E2 Q33438732-E29CAB43-F406-4A1D-A53A-ACB3D4DD8367 Q33649853-6D8253F0-15F7-4344-9591-9294EAD4C289 Q33709629-31EDC41C-D455-4AF1-858A-764D4CB1FB8F Q33761796-47F09329-8E88-4799-8135-C53C97D6C75F Q33779854-202CFDDE-3705-44A0-809F-11201918EE80 Q36047009-2011FDED-F5E5-4489-97AF-5A2DEB0BFF04 Q36100847-A6FCAB0A-1664-45B0-A2E8-2F6465112A58 Q36184617-C59B4D7B-D269-4024-944B-C62A81759EAA Q36256046-3C49A2A3-62B7-45F6-945E-81B12D1D610C Q36288278-57266C03-F1A8-49A8-A0DE-25166535F01A Q36290436-6A6002E1-7B3C-4CF2-8FF6-3BA9E11E20BB Q36319273-0B9B8750-B5B1-4C0D-A3AE-E5A9F826CE59 Q36379340-6AE0AD8E-7123-4F19-9C86-4149E1F80057 Q36393629-49B5B45A-C842-4969-8336-65724615207A Q37085681-ACF5157B-F7DD-4C0C-AC0D-DD39E414CD62 Q37097358-4D3A1676-53CE-4A05-9057-C410F3B06D1B Q37144116-D507C9D0-982C-4DDC-AF7C-861D0E7636BA Q37571496-32336E28-CF8A-47B8-803C-8C5E1B4022BD Q37636533-242ABA13-F58F-4CD2-BA31-7DAC1163A569 Q37688959-F602EBBC-DB00-44B0-8EAB-C1B3ABCAB763 Q37721580-08DBBBE4-74E8-4B57-95DE-D11592BA8A38 Q38605491-0E6F6BFF-E2B1-474D-A808-57CBA5B0F518 Q38662513-358D747C-28A7-4A51-B451-68AF628B3F61 Q38695555-E98137EE-DA21-4F6A-A249-8C7EDF1E4AD8 Q38720601-92788F08-60E4-4608-8AD6-D1B4D60B6141 Q38721999-25D71A32-300F-4F16-805F-0BFD679AC30D Q38725438-38651FF0-BA40-4B4C-9116-8277EF63E0E1 Q38729360-A5165E63-02F0-46CA-A8EE-CB07642B7D27 Q38735021-134FBB54-D62F-41DF-8A18-54D0A15611A9

P2860

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

http://www.wikidata.org/entity/Q35214924

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@ast

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@en

type

label

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@ast

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@en

prefLabel

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@ast

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@en

P1433

Q35214924-13D066A2-B134-411F-BB5B-D0EA23C853EC

P1476

Q35214924-A1862D26-A3BF-4123-A677-A1E8698318AC

P2093

Q35214924-21BB7C16-5473-4DE4-8AC5-99F9B0F4ED70

Q35214924-B659D4E3-4537-459A-904F-5BC651E9DFDA

Q35214924-E0DC8DAE-EBC2-47F8-B0EA-13F6A9CFEA17

Q35214924-FDE090AA-746B-4183-AA06-F575D8DB7D8F

P275

Q35214924-ECFE409C-C2A0-416A-894D-F2789E14B43D

P2860

Q35214924-001BCAD5-1EEB-4BA8-AB21-46DE3799D871

Q35214924-0216BF80-BA3F-426F-8988-9EC970C9F93A

Q35214924-06096425-D09B-4B81-AD6A-9084584019B9

Q35214924-06406382-E563-48EC-8E8D-D97DF3D08401

Q35214924-097B055A-CDA2-4E23-A532-9F8CA7C90358

Q35214924-0D06F993-3A85-4F7B-82AE-7CB3B4AE445A

Q35214924-0D3904BD-FE64-453E-8CA1-E5CFF337CC8A

Q35214924-0F8B4305-156F-464A-A773-D7DB51ABC2F7

Q35214924-10C7A94D-825A-410B-AE06-F0DA9989E1E8

Q35214924-11ECD00E-FEBE-4E7D-A141-FA5823740AF3

P304

Q35214924-70077988-400A-41EA-A11A-4EA81830930B

P31

Q35214924-6DBD10F9-D6F2-4ADF-9C4F-2752B4AA6C39

Q35214924-BC3D6E13-C174-461B-B58F-0ABF8658F684

P356

Q35214924-29845D2D-9CE8-4DE6-9BFC-356E6487C2D8

P407

Q35214924-E91ABF2E-96E7-4D20-9C23-AAA21F3DB208

P433

Q35214924-11754E90-EF6C-4BDC-8E31-FA70774F2F85

P478

Q35214924-9F2A7F44-0D02-4AC8-B214-82647CC6E801

P5008

Q35214924-B56EC38F-3297-4C6F-8031-AAFFD971645D

P577

Q35214924-15E61CC6-E384-4D2C-94B2-250207A667D7

P5875

Q35214924-EE417DE2-F2E8-4176-AFB9-9CB73F7BDC16

P698

Q35214924-14418F63-2342-4451-9B39-35BEBA01BB6E

P921

Q35214924-9FAC886A-DCB0-4583-89A7-576CE9BBB746

Q35214924-CBECC0B0-EEF7-4F62-8CD6-E0635BCAAD84

Q35214924-E847AEFB-463C-4E9E-A17C-93A28B79813B

P932

Q35214924-F3228286-0EC7-4979-BCA1-3CA7B8BEC421

P356

MOLECULES20033898

P1433

P1476

Histone deacetylase inhibitors ...... tes for new anticancer agents.

@en

P2093

Guangdi Wang

http://www.w3.org/2001/XMLSchema#string

Madhusoodanan Mottamal

http://www.w3.org/2001/XMLSchema#string

Shilong Zheng

http://www.w3.org/2001/XMLSchema#string

Tien L Huang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Sirtuins as regulators of metabolism and healthspan

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

Chromatin modifications and their function

P304

3898-3941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/MOLECULES20033898

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273787331

http://www.w3.org/2001/XMLSchema#string

P698

25738536

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

4372801

http://www.w3.org/2001/XMLSchema#string